Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 7, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open‑market trades under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, she directly holds 49,513 common shares and also has additional indirect holdings through family trusts and her spouse.
United Therapeutics executive vice president and general counsel Paul A. Mahon exercised stock options and sold the resulting shares in a planned transaction. On May 7, 2026, he exercised options for 8,300 shares of common stock at a strike price of $146.03 per share and carried out open‑market sales totaling 8,300 shares.
The sales were executed in multiple trades at prices including about $597.54, $596.19, $588.51 and several weighted‑average prices in the mid‑$580s, according to footnotes. The filing states these transactions were made under a pre‑arranged Rule 10b5‑1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at $146.03 per share, then sold 9,500 shares in multiple open-market trades, including 1,513 shares at $595.02 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The filing also lists substantial indirect holdings in family trusts and by her spouse.
Paul Mahon submitted a Form 144 notice to sell 8,300 shares of Common Stock associated with a Stock Option Exercise dated 05/07/2026. The filing lists prior sales of 8,300-share blocks on 04/16/2026, 04/02/2026, 03/19/2026, 03/05/2026, and 02/19/2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold common shares in a planned sequence. On May 5, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open-market trades around the high-$500s.
The filing shows these actions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, designed to run until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. After the transactions, she directly holds 40,513 common shares and also has additional indirect holdings through various family trusts and a spouse account.
United Therapeutics reported softer first quarter 2026 results, with revenue and profit declining versus last year. Total revenues fell 2% to $781.5 million from $794.4 million, while net income declined 15% to $274.9 million. Diluted earnings per share decreased to $5.82 from $6.63.
Tyvaso DPI revenues grew 9% to $330.3 million, but were offset by lower Nebulized Tyvaso and Remodulin sales, resulting in a 2% decline in total Tyvaso revenues to $457.5 million. Cost of sales rose sharply, partly due to a $26.8 million estimated loss on a Tyvaso DPI commercial supply agreement.
The company authorized a share repurchase program of up to $2.0 billion through March 9, 2027 and entered into accelerated share repurchase agreements for approximately $1.5 billion. During the quarter it received 2,164,459 shares, leaving $500 million available under the authorization. Cash, cash equivalents, and marketable investments totaled $3.47 billion as of March 31, 2026.
United Therapeutics reported quarterly net income of $274.9M, down from $322.2M a year earlier, on total revenues of $781.5M versus $794.4M. Higher cost of sales, including Tyvaso DPI inventory reserves and a $26.8M loss tied to a supply agreement, compressed operating income.
The company executed a large capital return, recording a $1.5B accelerated share repurchase in March 2026 under a new $2.0B program, following completion of a prior $1.0B program. Cash and cash equivalents were $1,279.7M and marketable investments $2,191.4M as of March 31, 2026, supporting continued R&D investment.
Phase 3 data were strong for key pipeline assets. Nebulized Tyvaso met primary endpoints in two IPF studies (TETON-1 and TETON-2), with integrated analysis showing a 111.8 mL absolute FVC benefit versus placebo at week 52 (p<0.0001). The ADVANCE OUTCOMES trial of oral ralinepag reduced risk of clinical worsening in PAH by 55% (hazard ratio 0.45, p<0.0001), with significant secondary endpoint improvements, and the company is preparing U.S. regulatory filings.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options to acquire 9,500 shares of common stock at $146.03 per share, then sold 9,500 shares in multiple open‑market trades at prices between roughly $568 and $583. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
After the transactions, she held 49,973 shares directly and maintained substantial indirect holdings through family trusts and her spouse, including 324,443, 258,117 and 45,596 shares. The trading plan will continue until either 1,734,410 stock options expiring on March 17, 2027 are exercised or December 31, 2026, whichever occurs first.
UNITED THERAPEUTICS Corp Chief Financial Officer and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On May 4, 2026, he exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share and sold 10,000 shares in multiple open-market trades at prices generally between the high $560s and low $580s per share. The filing states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the timing was scheduled in advance. After the transactions, Edgemond continues to hold 18,876 shares of common stock directly, along with 32,500 stock options, signaling he retains a meaningful equity stake in UNITED THERAPEUTICS.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at $146.03 per share and sold 9,500 shares in open-market trades on May 1, 2026. The sales occurred at prices around $565.78–$571.95 per share in multiple transactions.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until up to 1,734,410 options are exercised or until December 31, 2026. Following the transactions, Rothblatt holds 40,513 shares directly, plus additional indirect holdings through family trusts and a spouse account.